PDB Short entry for 2CCI HEADER CELL CYCLE 16-JAN-06 2CCI TITLE CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE TITLE 2 CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 COMPND MOL_ID: 1; COMPND 2 MOLECULE: CYCLIN-DEPENDENT KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: CELL DIVISION PROTEIN KINASE 2,P33 PROTEIN KINASE; COMPND 5 EC: 2.7.11.22; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: PHOSPHORYLATED AT RESIDUE T160; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLIN-A2; COMPND 10 CHAIN: B, D; COMPND 11 FRAGMENT: RESIDUES 175-432; COMPND 12 SYNONYM: CYCLIN-A,CYCLIN A; COMPND 13 ENGINEERED: YES; COMPND 14 MOL_ID: 3; COMPND 15 MOLECULE: CELL DIVISION CONTROL PROTEIN 6 HOMOLOG; COMPND 16 CHAIN: F, I; COMPND 17 FRAGMENT: RESIDUES 71-100; COMPND 18 SYNONYM: CDC6-RELATED PROTEIN,CDC18-RELATED PROTEIN,HSCDC18, COMPND 19 P62(CDC6),HSCDC6; COMPND 20 ENGINEERED: YES; COMPND 21 MUTATION: YES; COMPND 22 OTHER_DETAILS: PEPTIDE MODIFIED TO GENERATE ACTIVE SITE SEQUENCE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CDK2, CDKN2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: B834; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PGEX; SOURCE 10 MOL_ID: 2; SOURCE 11 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 12 ORGANISM_COMMON: HUMAN; SOURCE 13 ORGANISM_TAXID: 9606; SOURCE 14 GENE: CCNA2, CCN1, CCNA; SOURCE 15 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 16 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 17 EXPRESSION_SYSTEM_STRAIN: B834; SOURCE 18 EXPRESSION_SYSTEM_PLASMID: PET21D; SOURCE 19 MOL_ID: 3; SOURCE 20 SYNTHETIC: YES; SOURCE 21 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 22 ORGANISM_COMMON: HUMAN; SOURCE 23 ORGANISM_TAXID: 9606 KEYWDS COMPLEX (TRANSFERASE-CELL DIVISION), PROTEIN KINASES, CELL CYCLE, KEYWDS 2 RECRUITMENT, SUBSTRATE RECOGNITION, ATP-BINDING, CELL DIVISION, KEYWDS 3 KINASE, MITOSIS, NUCLEOTIDE-BINDING, PHOSPHORYLATION, KEYWDS 4 SERINE/THREONINE- PROTEIN KINASE, TRANSFERASE, CYCLIN, DNA KEYWDS 5 REPLICATION, NUCLEAR PROTEIN, COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR K.Y.CHENG,M.E.M.NOBLE,V.SKAMNAKI,N.R.BROWN,E.D.LOWE,L.KONTOGIANNIS, AUTHOR 2 K.SHEN,P.A.COLE,G.SILIGARDI,L.N.JOHNSON REVDAT 6 13-DEC-23 2CCI 1 LINK REVDAT 5 06-JUN-18 2CCI 1 COMPND SOURCE JRNL DBREF REVDAT 5 2 1 SEQADV REVDAT 4 13-JUL-11 2CCI 1 VERSN REVDAT 3 24-FEB-09 2CCI 1 VERSN REVDAT 2 09-AUG-06 2CCI 1 JRNL REVDAT 1 03-MAY-06 2CCI 0 JRNL AUTH K.Y.CHENG,M.E.NOBLE,V.SKAMNAKI,N.R.BROWN,E.D.LOWE, JRNL AUTH 2 L.KONTOGIANNIS,K.SHEN,P.A.COLE,G.SILIGARDI,L.N.JOHNSON JRNL TITL THE ROLE OF THE PHOSPHO-CDK2/CYCLIN A RECRUITMENT SITE IN JRNL TITL 2 SUBSTRATE RECOGNITION. JRNL REF J. BIOL. CHEM. V. 281 23167 2006 JRNL REFN ISSN 0021-9258 JRNL PMID 16707497 JRNL DOI 10.1074/JBC.M600480200 REMARK 2 REMARK 2 RESOLUTION. 2.70 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0005 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.70 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 94.92 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 97.0 REMARK 3 NUMBER OF REFLECTIONS : 37597 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.264 REMARK 3 R VALUE (WORKING SET) : 0.261 REMARK 3 FREE R VALUE : 0.321 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1996 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.70 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.77 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2760 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.3560 REMARK 3 BIN FREE R VALUE SET COUNT : 154 REMARK 3 BIN FREE R VALUE : 0.4320 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 9216 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 64 REMARK 3 SOLVENT ATOMS : 111 REMARK 3 REMARK 3 B VALUES. REMARK 3 B VALUE TYPE : LIKELY RESIDUAL REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 37.66 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -1.57000 REMARK 3 B22 (A**2) : 0.50000 REMARK 3 B33 (A**2) : 1.07000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 12.217 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.446 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.347 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 34.164 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.838 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.775 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 9509 ; 0.008 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 12917 ; 1.146 ; 1.986 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1135 ; 5.337 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 407 ;39.457 ;23.735 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 1671 ;17.130 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 50 ;17.830 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1459 ; 0.077 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 7024 ; 0.003 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 4507 ; 0.200 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 6433 ; 0.303 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 337 ; 0.138 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 86 ; 0.179 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 3 ; 0.278 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 5888 ; 0.285 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 9300 ; 0.506 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 4105 ; 0.657 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3617 ; 1.104 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 4 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 0 A 296 REMARK 3 ORIGIN FOR THE GROUP (A): 25.3755 40.8399 3.3747 REMARK 3 T TENSOR REMARK 3 T11: -0.2853 T22: -0.1761 REMARK 3 T33: -0.1829 T12: 0.0320 REMARK 3 T13: -0.0210 T23: -0.0102 REMARK 3 L TENSOR REMARK 3 L11: 1.5096 L22: 1.9782 REMARK 3 L33: 1.3512 L12: 0.7549 REMARK 3 L13: 0.2030 L23: -0.1575 REMARK 3 S TENSOR REMARK 3 S11: -0.0873 S12: 0.0857 S13: 0.2090 REMARK 3 S21: 0.0409 S22: 0.0382 S23: 0.1389 REMARK 3 S31: -0.2132 S32: -0.1091 S33: 0.0491 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : B 175 B 432 REMARK 3 ORIGIN FOR THE GROUP (A): 41.1468 38.4769 32.4078 REMARK 3 T TENSOR REMARK 3 T11: -0.2469 T22: -0.1294 REMARK 3 T33: -0.2906 T12: -0.0097 REMARK 3 T13: -0.0175 T23: -0.0090 REMARK 3 L TENSOR REMARK 3 L11: 1.6144 L22: 2.3564 REMARK 3 L33: 1.6912 L12: -0.6575 REMARK 3 L13: -0.5265 L23: 0.3242 REMARK 3 S TENSOR REMARK 3 S11: -0.0607 S12: -0.1652 S13: -0.0443 REMARK 3 S21: 0.1825 S22: 0.0320 S23: 0.0236 REMARK 3 S31: -0.0259 S32: 0.0618 S33: 0.0287 REMARK 3 REMARK 3 TLS GROUP : 3 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : C 0 C 296 REMARK 3 ORIGIN FOR THE GROUP (A): 8.7375 21.7896 54.1547 REMARK 3 T TENSOR REMARK 3 T11: 0.0435 T22: 0.0710 REMARK 3 T33: -0.0152 T12: 0.1156 REMARK 3 T13: -0.0422 T23: -0.0075 REMARK 3 L TENSOR REMARK 3 L11: 3.1107 L22: 1.8822 REMARK 3 L33: 1.9067 L12: -0.7020 REMARK 3 L13: -1.2662 L23: 0.2110 REMARK 3 S TENSOR REMARK 3 S11: 0.0583 S12: 0.2798 S13: 0.2579 REMARK 3 S21: -0.2011 S22: -0.1004 S23: 0.2718 REMARK 3 S31: -0.4407 S32: -0.4593 S33: 0.0421 REMARK 3 REMARK 3 TLS GROUP : 4 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : D 175 D 432 REMARK 3 ORIGIN FOR THE GROUP (A): 10.8716 10.6441 85.3526 REMARK 3 T TENSOR REMARK 3 T11: 0.1141 T22: -0.0672 REMARK 3 T33: -0.0501 T12: 0.0551 REMARK 3 T13: 0.1119 T23: 0.0140 REMARK 3 L TENSOR REMARK 3 L11: 3.3876 L22: 2.3707 REMARK 3 L33: 1.5269 L12: -0.2582 REMARK 3 L13: -0.2503 L23: 0.1664 REMARK 3 S TENSOR REMARK 3 S11: -0.2111 S12: -0.1738 S13: -0.1159 REMARK 3 S21: 0.4579 S22: 0.0835 S23: 0.4207 REMARK 3 S31: 0.0126 S32: -0.3151 S33: 0.1276 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2CCI COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 16-JAN-06. REMARK 100 THE DEPOSITION ID IS D_1290027145. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-NOV-05 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 5.60 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.933 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 39629 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.700 REMARK 200 RESOLUTION RANGE LOW (A) : 40.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.6 REMARK 200 DATA REDUNDANCY : 2.200 REMARK 200 R MERGE (I) : 0.12000 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 10.4000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.70 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.85 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.5 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.31000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 2.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: PDB ENTRY 1QMZ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.80 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 10-17% (V/V) PEG MONOMETHYLETHER 5000, REMARK 280 0.2 M AMMONIUM SULPHATE AND 0.1 M MES PH 5.0-6.5, PH 5.60 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 37.21000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 85.35450 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 57.19450 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 85.35450 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 37.21000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 57.19450 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D, I REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 INVOLVED IN THE CONTROL OF THE CELL CYCLE REMARK 400 ENGINEERED RESIDUE IN CHAIN F, PRO 71 TO HIS REMARK 400 ENGINEERED RESIDUE IN CHAIN F, PRO 72 TO HIS REMARK 400 ENGINEERED RESIDUE IN CHAIN F, CYS 73 TO ALA REMARK 400 ENGINEERED RESIDUE IN CHAIN F, PRO 76 TO ARG REMARK 400 ENGINEERED RESIDUE IN CHAIN I, PRO 71 TO HIS REMARK 400 ENGINEERED RESIDUE IN CHAIN I, PRO 72 TO HIS REMARK 400 ENGINEERED RESIDUE IN CHAIN I, CYS 73 TO ALA REMARK 400 ENGINEERED RESIDUE IN CHAIN I, PRO 76 TO ARG REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG A 297 REMARK 465 LEU A 298 REMARK 465 ARG C 297 REMARK 465 LEU C 298 REMARK 465 GLN F 74 REMARK 465 GLY F 75 REMARK 465 LYS F 76 REMARK 465 LYS F 77 REMARK 465 GLU F 78 REMARK 465 ASN F 79 REMARK 465 GLY F 80 REMARK 465 PRO F 81 REMARK 465 PRO F 82 REMARK 465 HIS F 83 REMARK 465 SER F 84 REMARK 465 HIS I 67 REMARK 465 HIS I 68 REMARK 465 GLN I 74 REMARK 465 GLY I 75 REMARK 465 LYS I 76 REMARK 465 LYS I 77 REMARK 465 GLU I 78 REMARK 465 ASN I 79 REMARK 465 GLY I 80 REMARK 465 PRO I 81 REMARK 465 PRO I 82 REMARK 465 HIS I 83 REMARK 465 SER I 84 REMARK 465 HIS I 85 REMARK 465 ASP I 95 REMARK 465 ASN I 96 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 12 104.41 22.79 REMARK 500 THR A 14 -22.55 56.48 REMARK 500 ASP A 38 -159.44 78.66 REMARK 500 GLU A 40 9.79 80.58 REMARK 500 THR A 41 -159.91 -77.28 REMARK 500 HIS A 71 61.35 -109.98 REMARK 500 LEU A 96 -79.29 -83.65 REMARK 500 ARG A 126 13.15 58.22 REMARK 500 ASP A 127 40.60 -148.27 REMARK 500 ASP A 145 81.43 48.01 REMARK 500 VAL A 164 131.30 76.14 REMARK 500 SER A 181 -161.43 -163.20 REMARK 500 TRP A 227 83.26 -154.36 REMARK 500 ASP B 177 -64.18 -11.35 REMARK 500 THR B 303 17.84 46.98 REMARK 500 PHE B 304 13.81 80.07 REMARK 500 TRP B 372 115.48 -31.92 REMARK 500 GLU C 12 75.88 -117.28 REMARK 500 THR C 14 -59.82 38.34 REMARK 500 ASP C 38 -127.68 46.38 REMARK 500 GLU C 40 -13.37 78.88 REMARK 500 SER C 94 32.62 -84.56 REMARK 500 ARG C 122 51.18 39.25 REMARK 500 ASP C 127 51.48 -153.85 REMARK 500 PRO C 130 -59.68 -28.81 REMARK 500 ASN C 136 -158.80 -103.60 REMARK 500 ASP C 145 86.76 64.10 REMARK 500 VAL C 164 137.90 71.13 REMARK 500 LEU C 166 -60.17 -29.15 REMARK 500 SER C 181 -157.22 -152.71 REMARK 500 ARG C 199 -38.70 72.78 REMARK 500 TRP C 227 84.54 -154.04 REMARK 500 SER C 239 33.77 -93.83 REMARK 500 ARG C 245 104.89 -57.77 REMARK 500 LEU C 281 9.75 -66.97 REMARK 500 PRO C 284 -8.71 -55.84 REMARK 500 CYS D 193 35.72 -77.10 REMARK 500 THR D 303 36.69 37.61 REMARK 500 VAL D 367 -66.84 -98.81 REMARK 500 TRP D 372 106.44 -53.73 REMARK 500 ASN D 415 -161.16 -72.40 REMARK 500 HIS D 419 -26.45 67.92 REMARK 500 ASN D 431 82.57 53.83 REMARK 500 HIS F 68 121.32 95.80 REMARK 500 ARG I 72 -164.56 -126.68 REMARK 500 LEU I 87 84.28 54.10 REMARK 500 LEU I 92 101.85 51.06 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MG A1298 MG REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASN A 132 OD1 REMARK 620 2 ASP A 145 OD1 83.6 REMARK 620 3 ATP A1297 O3B 134.6 93.4 REMARK 620 4 ATP A1297 O1A 76.5 69.3 60.5 REMARK 620 N 1 2 3 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MG C1298 MG REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASN C 132 ND2 REMARK 620 2 ASN C 132 OD1 49.6 REMARK 620 3 ASP C 145 OD1 68.2 72.4 REMARK 620 4 ATP C1297 O1G 124.0 75.3 88.1 REMARK 620 5 ATP C1297 O2B 121.4 105.2 53.1 58.0 REMARK 620 6 ATP C1297 O3G 169.0 125.5 121.4 54.9 68.4 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MG A1298 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MG C1298 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ATP A1297 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ATP C1297 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1OKU RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ALA- ALA-ABU-ARG-ER-LEU-ILE-(P- REMARK 900 F-PHE)-NH2 REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO- INDIRUBINE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5T RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE REMARK 900 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 999 REMARK 999 SEQUENCE REMARK 999 CHAINS B AND D ARE A TRUNCATED FRAGMENT OF CYCLIN A2 REMARK 999 CONSISTING OF RESIDUES 175-432 REMARK 999 THE PEPTIDE CONTAINS RESIDUES 71-100 OF CDC6 WITH THE REMARK 999 FIRST SEVEN PEPTIDES MODIFIED TO GENERATE AN IDEAL REMARK 999 SUBSTRATE DBREF 2CCI A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2CCI B 175 432 UNP P20248 CCNA2_HUMAN 175 432 DBREF 2CCI C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 2CCI D 175 432 UNP P20248 CCNA2_HUMAN 175 432 DBREF 2CCI F 67 96 UNP Q99741 CDC6_HUMAN 71 100 DBREF 2CCI I 67 96 UNP Q99741 CDC6_HUMAN 71 100 SEQADV 2CCI SER A 0 UNP P24941 EXPRESSION TAG SEQADV 2CCI SER C 0 UNP P24941 EXPRESSION TAG SEQADV 2CCI HIS F 67 UNP Q99741 PRO 71 ENGINEERED MUTATION SEQADV 2CCI HIS F 68 UNP Q99741 PRO 72 ENGINEERED MUTATION SEQADV 2CCI ALA F 69 UNP Q99741 CYS 73 ENGINEERED MUTATION SEQADV 2CCI ARG F 72 UNP Q99741 PRO 76 ENGINEERED MUTATION SEQADV 2CCI HIS I 67 UNP Q99741 PRO 71 ENGINEERED MUTATION SEQADV 2CCI HIS I 68 UNP Q99741 PRO 72 ENGINEERED MUTATION SEQADV 2CCI ALA I 69 UNP Q99741 CYS 73 ENGINEERED MUTATION SEQADV 2CCI ARG I 72 UNP Q99741 PRO 76 ENGINEERED MUTATION SEQRES 1 A 299 SER MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU SEQRES 2 A 299 GLY THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU SEQRES 3 A 299 THR GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP SEQRES 4 A 299 THR GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU SEQRES 5 A 299 ILE SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL SEQRES 6 A 299 LYS LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR SEQRES 7 A 299 LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE SEQRES 8 A 299 MET ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU SEQRES 9 A 299 ILE LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA SEQRES 10 A 299 PHE CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS SEQRES 11 A 299 PRO GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS SEQRES 12 A 299 LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO SEQRES 13 A 299 VAL ARG THR TYR TPO HIS GLU VAL VAL THR LEU TRP TYR SEQRES 14 A 299 ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER SEQRES 15 A 299 THR ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA SEQRES 16 A 299 GLU MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER SEQRES 17 A 299 GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY SEQRES 18 A 299 THR PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET SEQRES 19 A 299 PRO ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN SEQRES 20 A 299 ASP PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY SEQRES 21 A 299 ARG SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN SEQRES 22 A 299 LYS ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE SEQRES 23 A 299 PHE GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 B 258 VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU ARG SEQRES 2 B 258 GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR MET SEQRES 3 B 258 LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA ILE SEQRES 4 B 258 LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR LYS SEQRES 5 B 258 LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR ILE SEQRES 6 B 258 ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY LYS SEQRES 7 B 258 LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SER SEQRES 8 B 258 LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU PHE SEQRES 9 B 258 VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN VAL SEQRES 10 B 258 LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR PHE SEQRES 11 B 258 ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR GLN SEQRES 12 B 258 TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL GLU SEQRES 13 B 258 SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE ASP SEQRES 14 B 258 ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE ALA SEQRES 15 B 258 GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR GLY SEQRES 16 B 258 GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY TYR SEQRES 17 B 258 THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU HIS SEQRES 18 B 258 GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SER SEQRES 19 B 258 ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY VAL SEQRES 20 B 258 SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 299 SER MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU SEQRES 2 C 299 GLY THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU SEQRES 3 C 299 THR GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP SEQRES 4 C 299 THR GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU SEQRES 5 C 299 ILE SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL SEQRES 6 C 299 LYS LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR SEQRES 7 C 299 LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE SEQRES 8 C 299 MET ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU SEQRES 9 C 299 ILE LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA SEQRES 10 C 299 PHE CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS SEQRES 11 C 299 PRO GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS SEQRES 12 C 299 LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO SEQRES 13 C 299 VAL ARG THR TYR TPO HIS GLU VAL VAL THR LEU TRP TYR SEQRES 14 C 299 ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER SEQRES 15 C 299 THR ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA SEQRES 16 C 299 GLU MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER SEQRES 17 C 299 GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY SEQRES 18 C 299 THR PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET SEQRES 19 C 299 PRO ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN SEQRES 20 C 299 ASP PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY SEQRES 21 C 299 ARG SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN SEQRES 22 C 299 LYS ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE SEQRES 23 C 299 PHE GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU SEQRES 1 D 258 VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR LEU ARG SEQRES 2 D 258 GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY TYR MET SEQRES 3 D 258 LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG ALA ILE SEQRES 4 D 258 LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU TYR LYS SEQRES 5 D 258 LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN TYR ILE SEQRES 6 D 258 ASP ARG PHE LEU SER SER MET SER VAL LEU ARG GLY LYS SEQRES 7 D 258 LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU ALA SER SEQRES 8 D 258 LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA GLU PHE SEQRES 9 D 258 VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS GLN VAL SEQRES 10 D 258 LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU THR PHE SEQRES 11 D 258 ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU THR GLN SEQRES 12 D 258 TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS VAL GLU SEQRES 13 D 258 SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU ILE ASP SEQRES 14 D 258 ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL ILE ALA SEQRES 15 D 258 GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL THR GLY SEQRES 16 D 258 GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR GLY TYR SEQRES 17 D 258 THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP LEU HIS SEQRES 18 D 258 GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN GLN SER SEQRES 19 D 258 ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS GLY VAL SEQRES 20 D 258 SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 F 30 HIS HIS ALA SER PRO ARG LYS GLN GLY LYS LYS GLU ASN SEQRES 2 F 30 GLY PRO PRO HIS SER HIS THR LEU LYS GLY ARG ARG LEU SEQRES 3 F 30 VAL PHE ASP ASN SEQRES 1 I 30 HIS HIS ALA SER PRO ARG LYS GLN GLY LYS LYS GLU ASN SEQRES 2 I 30 GLY PRO PRO HIS SER HIS THR LEU LYS GLY ARG ARG LEU SEQRES 3 I 30 VAL PHE ASP ASN MODRES 2CCI TPO A 160 THR MODIFIED RESIDUE MODRES 2CCI TPO C 160 THR MODIFIED RESIDUE HET TPO A 160 11 HET TPO C 160 11 HET ATP A1297 31 HET MG A1298 1 HET ATP C1297 31 HET MG C1298 1 HETNAM TPO PHOSPHOTHREONINE HETNAM ATP ADENOSINE-5'-TRIPHOSPHATE HETNAM MG MAGNESIUM ION HETSYN TPO PHOSPHONOTHREONINE FORMUL 1 TPO 2(C4 H10 N O6 P) FORMUL 7 ATP 2(C10 H16 N5 O13 P3) FORMUL 8 MG 2(MG 2+) FORMUL 11 HOH *111(H2 O) HELIX 1 1 PRO A 45 LYS A 56 1 12 HELIX 2 2 LEU A 87 ALA A 93 1 7 HELIX 3 3 PRO A 100 HIS A 121 1 22 HELIX 4 4 LYS A 129 GLN A 131 5 3 HELIX 5 5 THR A 165 ARG A 169 5 5 HELIX 6 6 ALA A 170 LEU A 175 1 6 HELIX 7 7 THR A 182 ARG A 199 1 18 HELIX 8 8 SER A 207 GLY A 220 1 14 HELIX 9 9 GLY A 229 MET A 233 5 5 HELIX 10 10 ASP A 247 VAL A 251 5 5 HELIX 11 11 ASP A 256 LEU A 267 1 12 HELIX 12 12 SER A 276 LEU A 281 1 6 HELIX 13 13 ALA A 282 GLN A 287 5 6 HELIX 14 14 VAL B 175 ASP B 177 5 3 HELIX 15 15 TYR B 178 CYS B 193 1 16 HELIX 16 16 THR B 207 LYS B 226 1 20 HELIX 17 17 GLN B 228 SER B 244 1 17 HELIX 18 18 LEU B 249 GLY B 251 5 3 HELIX 19 19 LYS B 252 GLU B 269 1 18 HELIX 20 20 GLU B 274 ILE B 281 1 8 HELIX 21 21 THR B 287 LEU B 302 1 16 HELIX 22 22 THR B 310 LEU B 320 1 11 HELIX 23 23 ASN B 326 ASP B 343 1 18 HELIX 24 24 ASP B 343 LEU B 348 1 6 HELIX 25 25 LEU B 351 THR B 368 1 18 HELIX 26 26 PRO B 373 GLY B 381 1 9 HELIX 27 27 LEU B 387 ALA B 401 1 15 HELIX 28 28 PRO B 402 HIS B 404 5 3 HELIX 29 29 GLN B 407 TYR B 413 1 7 HELIX 30 30 LYS B 414 HIS B 419 5 6 HELIX 31 31 GLY B 420 LEU B 424 5 5 HELIX 32 32 PRO C 45 GLU C 57 1 13 HELIX 33 33 LEU C 87 SER C 94 1 8 HELIX 34 34 PRO C 100 HIS C 121 1 22 HELIX 35 35 LYS C 129 GLN C 131 5 3 HELIX 36 36 THR C 165 ARG C 169 5 5 HELIX 37 37 ALA C 170 LEU C 175 1 6 HELIX 38 38 THR C 182 ARG C 199 1 18 HELIX 39 39 SER C 207 GLY C 220 1 14 HELIX 40 40 ASP C 247 VAL C 252 1 6 HELIX 41 41 ASP C 256 HIS C 268 1 13 HELIX 42 42 SER C 276 LEU C 281 1 6 HELIX 43 43 ALA C 282 GLN C 287 5 6 HELIX 44 44 TYR D 178 CYS D 193 1 16 HELIX 45 45 THR D 207 TYR D 225 1 19 HELIX 46 46 GLN D 228 MET D 246 1 19 HELIX 47 47 LEU D 249 GLY D 251 5 3 HELIX 48 48 LYS D 252 GLU D 269 1 18 HELIX 49 49 GLU D 274 ILE D 281 1 8 HELIX 50 50 THR D 287 LEU D 302 1 16 HELIX 51 51 THR D 310 LEU D 320 1 11 HELIX 52 52 CYS D 327 SER D 340 1 14 HELIX 53 53 ASP D 343 LEU D 348 1 6 HELIX 54 54 LEU D 351 VAL D 367 1 17 HELIX 55 55 PRO D 373 GLY D 381 1 9 HELIX 56 56 LEU D 387 ALA D 401 1 15 HELIX 57 57 GLN D 407 TYR D 413 1 7 HELIX 58 58 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 LYS A 9 0 SHEET 2 AA 5 VAL A 18 ASN A 23 -1 O LYS A 20 N VAL A 7 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLY C 13 0 SHEET 2 CA 5 GLY C 16 ASN C 23 -1 O GLY C 16 N GLY C 13 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 LINK C TYR A 159 N TPO A 160 1555 1555 1.33 LINK C TPO A 160 N HIS A 161 1555 1555 1.33 LINK C TYR C 159 N TPO C 160 1555 1555 1.34 LINK C TPO C 160 N HIS C 161 1555 1555 1.33 LINK OD1 ASN A 132 MG MG A1298 1555 1555 2.34 LINK OD1 ASP A 145 MG MG A1298 1555 1555 1.91 LINK O3B ATP A1297 MG MG A1298 1555 1555 2.62 LINK O1A ATP A1297 MG MG A1298 1555 1555 2.96 LINK ND2 ASN C 132 MG MG C1298 1555 1555 2.81 LINK OD1 ASN C 132 MG MG C1298 1555 1555 2.50 LINK OD1 ASP C 145 MG MG C1298 1555 1555 2.49 LINK O1G ATP C1297 MG MG C1298 1555 1555 1.86 LINK O2B ATP C1297 MG MG C1298 1555 1555 3.14 LINK O3G ATP C1297 MG MG C1298 1555 1555 3.09 CISPEP 1 VAL A 154 PRO A 155 0 -4.00 CISPEP 2 GLN B 323 PRO B 324 0 -2.52 CISPEP 3 ASP B 345 PRO B 346 0 5.80 CISPEP 4 VAL C 154 PRO C 155 0 -5.81 CISPEP 5 GLN D 323 PRO D 324 0 -3.49 CISPEP 6 ASP D 345 PRO D 346 0 2.08 SITE 1 AC1 3 ASN A 132 ASP A 145 ATP A1297 SITE 1 AC2 4 LYS C 129 ASN C 132 ASP C 145 ATP C1297 SITE 1 AC3 18 GLY A 11 GLU A 12 GLY A 13 THR A 14 SITE 2 AC3 18 ALA A 31 LYS A 33 PHE A 80 GLU A 81 SITE 3 AC3 18 PHE A 82 LEU A 83 ASP A 86 GLN A 131 SITE 4 AC3 18 ASN A 132 LEU A 134 ASP A 145 MG A1298 SITE 5 AC3 18 HOH A2044 ARG F 72 SITE 1 AC4 15 ILE C 10 GLY C 11 GLY C 13 THR C 14 SITE 2 AC4 15 ALA C 31 LYS C 33 GLU C 81 LEU C 83 SITE 3 AC4 15 ASP C 86 GLN C 131 ASN C 132 LEU C 134 SITE 4 AC4 15 ASP C 145 MG C1298 HOH C2022 CRYST1 74.420 114.389 170.709 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013437 0.000000 0.000000 0.00000 SCALE2 0.000000 0.008742 0.000000 0.00000 SCALE3 0.000000 0.000000 0.005858 0.00000